Literature DB >> 28567776

Patient-reported outcomes (PROs) in chronic urticaria.

Kristian Moestrup1, Misbah N Ghazanfar1, Simon F Thomsen1,2.   

Abstract

Chronic urticaria is an itching skin disease which persists for more than 6 weeks. Chronic urticaria has great impact on the daily life of the patient, and the fluctuating nature of the symptoms complicates the monitoring and treatment of the disease. Currently, there are no reliable biomarkers to identify and measure disease activity in chronic spontaneous urticaria. Consequently, use of patient-reported outcomes (PROs) is crucial when evaluating and monitoring different aspects of chronic urticaria such as disease activity/severity, disease control, and quality of life. We present an overview of seven different PROs used in chronic urticaria and highlight their strengths, limitations, and use in clinical practice and research.
© 2017 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2017        PMID: 28567776     DOI: 10.1111/ijd.13668

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  5 in total

1.  Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia.

Authors:  Elizabeth García-Gómez; Edgardo Chapman; María Beatriz García-Paba; Jaime Ocampo-Gómez; Eduardo Egea-Bermejo; Gloria Garavito-De Egea; Luis Fang; Mauricio Sarrazola; Jorge Mario Sánchez-Caraballo; Carlos Serrano-Reyes; Diana Lucia Silva-Espinosa; Dolly Vanessa Rojas-Mejía; Sergio M Moreno
Journal:  Front Allergy       Date:  2022-05-20

2.  Treatment Patterns and Clinical Outcomes of Chronic Urticaria: Two-year Follow-up Results from the Scandinavian AWARE Study.

Authors:  Simon F Thomsen; Ellen C Pritzier; Chris D Anderson; Siri Juvik; Nicolas V Baust; Rikke Dodge; Anna-Karin Dahlborn; Christian Vestergaard
Journal:  Acta Derm Venereol       Date:  2022-04-07       Impact factor: 3.875

3.  Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America.

Authors:  Ivan Cherrez-Ojeda; Marcus Maurer; Jonathan A Bernstein; Emanuel Vanegas; Miguel Felix; German D Ramon; Luis Felipe Ensina; José Ignacio Larco Sousa; Edgar Emilio Matos Benavides; R Cardona Villa; P Latour Staffeld; Blanca María Morfin-Maciel; Jose Mori; Paul Wilches C; Valeria L Mata; Annia Cherrez
Journal:  World Allergy Organ J       Date:  2019-02-23       Impact factor: 4.084

4.  What Basophil Testing Tells Us About CSU Patients - Results of the CORSA Study.

Authors:  João Marcelino; Katrine Baumann; Per Stahl Skov; Maria Conceição Pereira Santos; Inga Wyroslak; Jörg Scheffel; Sabine Altrichter; Anders Woetmann; Manuel Pereira-Barbosa; Célia Costa; Marcus Maurer
Journal:  Front Immunol       Date:  2021-09-28       Impact factor: 7.561

Review 5.  The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management.

Authors:  Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; Maximiliano Gomez; Sandra Nora Gonzalez-Diaz; Bryan Martin; Mário Morais-Almeida; Jose Antonio Ortega Martell
Journal:  World Allergy Organ J       Date:  2021-06-01       Impact factor: 4.084

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.